अApnaFunda
Menu

RAINBOW CHILDRENS MEDICARE LTD (RAINBOW)

Health Services · Hospital/Nursing Management · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.48 / 100
Profitability 69Growth 42Balance sheet 32
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.33 / 100
Price 20Earnings 42FII/DII 36

Passes these screensConsistent compounders

Compare withAPOLLO HOSPITALS ENTERPRISES LMAX HEALTHCARE INSTITUTEASTER DM QUALITY CARE

Share price

Closing priceAdjusted for splits and bonus issues.

₹1,275.2 latest close · −11.4% over the last 90 sessions

₹1,200₹1,400₹1,600Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹1,200₹1,400₹1,600Jul 3Sep 4Nov 9

₹1,275.2 month-end · −5.6% over 12 months

₹1,200₹1,400Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹1,200₹1,400Nov '25May '26Nov '26

₹1,275.2 month-end · +18.8% over 3 years

₹1,200₹1,400₹1,600Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹1,200₹1,400₹1,600Nov '23May '25Nov '26

₹1,275.2 month-end · +149923.5% since Apr '19

₹0₹500₹1,000₹1,500Apr '19Jan '23Jan '24Dec '24Dec '25Nov '26 ₹0₹500₹1,000₹1,500Apr '19Jul '24Nov '26

52-week range ₹1084.00 to ₹1610.00 · 1-year volatility 23.9%

Was the rally earned?

-6%share price, 1 yearLower P/E held it back

Earnings helped, the multiple did not.

  • Per-share earnings added 10 points, but investors now pay less per rupee of profit (P/E 53.3x to 45.4x), which took 16 points back.
  • The share count barely moved.
Net profit growth: +9 pts. Points of the price return explained by net profit growing (or shrinking).+9 ptsNet profit growthP/E change: −16 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−16 ptsP/E changeShare count change: +1 pts. Points of the price return explained by the share count changing. More shares count against the price.+1 ptsShare count changeShare price: −6%−6%Share priceNet profit growth: +9 pts. Points of the price return explained by net profit growing (or shrinking).+9ProfitP/E change: −16 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−16P/EShare count change: +1 pts. Points of the price return explained by the share count changing. More shares count against the price.+1SharesShare price: −6%−6%Share price
Net profit growth+9 ptsNet profit rose about 10%, which lifts the price.
P/E change-16 ptsThe P/E fell from 53.3x to 45.4x, which lowers the price.
Share count change+1 ptsShare count was little changed. More shares would count against the price.
+19%share price, 3 yearsLower P/E held it back

Mostly yes, with a catch.

  • Per-share earnings added 33 points, but investors now pay less per rupee of profit (P/E 51.7x to 45.4x), which took 14 points back.
  • The share count barely moved.
Net profit growth: +32 pts. Points of the price return explained by net profit growing (or shrinking).+32 ptsNet profit growthP/E change: −14 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−14 ptsP/E changeShare count change: +1 pts. Points of the price return explained by the share count changing. More shares count against the price.+1 ptsShare count changeShare price: +19%+19%Share priceNet profit growth: +32 pts. Points of the price return explained by net profit growing (or shrinking).+32ProfitP/E change: −14 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−14P/EShare count change: +1 pts. Points of the price return explained by the share count changing. More shares count against the price.+1SharesShare price: +19%+19%Share price
Net profit growth+32 ptsNet profit rose about 35%, which lifts the price.
P/E change-14 ptsThe P/E fell from 51.7x to 45.4x, which lowers the price.
Share count change+1 ptsShare count was little changed. More shares would count against the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 5 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with APOLLO HOSPITALS ENTERPRISES L

How rough has the ride been?

Maximum drawdown-34.2%not yet recovered
1-year volatility23.9%annualised
Beta vs sector index0.613-year daily, correlation 0.33
Volume spikes1last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−10%−20%−30%2020202120222023202420252026−33.6% 0%−10%−20%−30%2020202220242026−33.6%
Largest drawdowns

-34.2% (2024-12 peak to 2026-03 low, not yet recovered)

-29.7% (2024-05 peak to 2024-07 low, recovered 2024-10)

-25.0% (2019-04 peak to 2019-06 low, recovered 2022-05)

Most recent volume spikes

2026-09-25: 5.4x the 50-day median, price -2.7% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

45.4xP/E todayNear its historic low
Against its own history11th percentile
CheapestMedian 53.5xDearest

Usual range 45.4x to 65.9x since 2019-04.

Against Health Services45.4x vs 50.9x
This company
45.4x
Sector median
50.9x

11% below the Health Services median.

29.7x56.2x82.8x109.3xApr '19Nov '20Jun '22Jan '24Aug '25Nov '2629.7x56.2x82.8x109.3xApr '19Nov '21Jun '24Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Services median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Services median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Services median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Services is valued

Where does it rank among Health Services peers?

Each cell is the company's percentile rank among its Health Services peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE59th▼ 10 pts vs a year ago
  • Op. margin78th▼ 5 pts vs a year ago
  • Revenue growth52nd▼ 5 pts vs a year ago
  • EPS growth45th▼ 15 pts vs a year ago
  • Debt/equity ↓29th▲ 8 pts vs a year ago
  • Cash cycle ↓73rd▼ 6 pts vs a year ago
  • P/E ↓58th▲ 3 pts vs a year ago
  • 12M momentum43rd▲ 22 pts vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Services sector page Watch it move against Health Services in the Observatory

What is the price implying?

~28%annual earnings growth implied by the priceIn line with delivered growth

At normalised P/E (five-year average earnings) of 60.3x, a holder earning 12%/yr needs earnings to grow about 28.0%/yr for 10 years, then trade at 15x.

Delivered27.3%/yrEPS, last 10 fiscal years · 3-yr avg to 3-yr avg
Gap+0.7 ptsimplied minus delivered
Rank512thmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

0%20%40% Jun 2020Nov 2026 0%20%40% Jun 2020Nov 2026

Change the assumptions

Exit P/E / return11%12%13%
12x29.6%30.8%32.0%
15x26.9%28.0%29.2%
20x23.4%24.5%25.6%

Drag a slider to test other assumptions

Implied: 28.0%/yr

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Services The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹1275.20
P/E
45.4x
ROCE
17.0%
Market Cap
₹12949 cr
Revenue (TTM)
₹1820 cr
P/S
7.1x
P/B
7.9x
ROE
17.3%
Operating Margin
29.0%
Debt / Equity
0.5x
Promoter Holding
49.8%
12M Momentum
-5.6%

52-week range

₹1084.00₹1610.00
36% of the way from its 52-week low to its high

Price risk

1Y volatility
23.9%
Beta vs sector
1-year daily
0.52

Balance sheet & cash

Interest cover
operating profit ÷ interest
5.7x
Cash from profit, 3Y
operating cash flow ÷ net profit
1.53x
Share count, 1Y
unchanged

Are profits backed by cash?

7 of 7checks within rangeAll clear
Other income reliance10%Within range

Other income as a share of pre-tax profit (trailing twelve months): 9.7%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate26%Within range

Median quarterly effective tax rate over about 2.5 years: 26.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion1.53xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 1.53x (cash from operations ₹1,137 cr, net profit ₹744 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow4 of 5 yrsWithin range

Fiscal years with positive free cash flow in the last 5: 4. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+3 daysWithin range

Debtor days are above the median of the previous three fiscal years by 3 days (22 vs 19). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress5% of fixed assetsWithin range

Capital work-in-progress is 5% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days-18 days / 2 yrsWithin range

Days payable changed by -18 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 3 years, DIIs added 7.2 pts; FIIs trimmed 5.6 pts.
  • The number of shareholders rose from 79,187 to 89,305 (+13%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change
Promoters49.8%49.8%0.0 pts
FIIs21.6%16.0%-5.6 pts
DIIs15.4%22.6%+7.2 pts
Public and others13.1%11.4%-1.8 pts

Number of shareholders

89,305shareholders+13% since Sep '23
77k81k85k89k Sep '23Jun '24Mar '25Dec '25Jun '26
Sep '23: 79,187
Dec '23: 80,471
Mar '24: 77,152
Jun '24: 78,557
Sep '24: 77,524
Dec '24: 78,764
Mar '25: 79,092
Jun '25: 80,320
Sep '25: 81,134
Dec '25: 88,809
Mar '26: 88,561
Jun '26: 89,305
 77k81k85k89k Sep '23Sep '24Sep '25Jun '26
Sep '23: 79,187
Dec '23: 80,471
Mar '24: 77,152
Jun '24: 78,557
Sep '24: 77,524
Dec '24: 78,764
Mar '25: 79,092
Jun '25: 80,320
Sep '25: 81,134
Dec '25: 88,809
Mar '26: 88,561
Jun '26: 89,305

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−0.6%typical 12-month return vs the marketNot meaningfully different from the base rate
  • We found 50 past situations where a non-financial company looked like RAINBOW CHILDRENS MEDICARE LTD today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −23% to +20% vs the market, against −3% for all non-financial companies in the same months.
  • The gap against the base rate (+2.7%, 80% range −12.6% to +8.2%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

−100%−50%0%+50%+100%
TATVA · Feb 2023: −57.6% vs market
HAPPSTMNDS · Feb 2025: −55.6% vs market
NAVINFLUOR · Jun 2023: −45.8% vs market
BATAINDIA · Apr 2025: −44.3% vs market
ZYDUSLIFE · May 2021: −43.4% vs market
EPL · Jan 2021: −42.9% vs market
BERGEPAINT · Jun 2023: −39.1% vs market
SYMPHONY · Jan 2023: −29.6% vs market
SUNDRMFAST · Nov 2023: −28.0% vs market
TORNTPHARM · Jan 2021: −24.7% vs market
SFL · Jun 2022: −24.2% vs market
SYNGENE · Aug 2023: −23.8% vs market
GODREJAGRO · Feb 2020: −23.3% vs market
GALAXYSURF · Jul 2022: −23.1% vs market
GODREJCP · Oct 2025: −22.7% vs market
JKCEMENT · May 2021: −22.6% vs market
JYOTHYLAB · Apr 2020: −21.1% vs market
DABUR · Apr 2025: −15.2% vs market
CROMPTON · Jun 2024: −14.2% vs market
SHREECEM · Sep 2020: −12.8% vs market
BALKRISIND · Jul 2025: −12.3% vs market
APOLLOHOSP · May 2023: −12.0% vs market
VGUARD · Jul 2024: −11.7% vs market
METROBRAND · Apr 2025: −10.4% vs market
MEDANTA · May 2025: −2.1% vs market
RAMCOCEM · Jul 2020: +0.8% vs market
CCL · Aug 2020: +2.6% vs market
JBCHEPHARM · Jul 2023: +4.1% vs market
TEGA · May 2025: +4.7% vs market
METROPOLIS · Apr 2025: +5.0% vs market
ANURAS · Jul 2022: +6.7% vs market
JLHL · Jul 2025: +10.0% vs market
MANKIND · Oct 2025: +10.5% vs market
LALPATHLAB · May 2025: +12.9% vs market
NH · Apr 2023: +14.3% vs market
ERIS · Aug 2023: +16.4% vs market
INDHOTEL · Jun 2024: +19.1% vs market
FLUOROCHEM · Oct 2025: +19.9% vs market
ELGIEQUIP · Feb 2020: +22.9% vs market
AARTIIND · Jan 2021: +25.2% vs market
BIKAJI · Apr 2024: +29.3% vs market
KIMS · Sep 2024: +36.3% vs market
VIJAYA · Jul 2024: +44.4% vs market
CRAFTSMAN · Nov 2022: +45.1% vs market
FORTIS · Jun 2024: +63.7% vs market
ASTRAMICRO · Jun 2025: +69.4% vs market
BLUEDART · May 2020: +72.4% vs market
SOLARINDS · Jun 2021: +73.1% vs market
CHOICEIN · Nov 2023: +88.9% vs market
SRF · Mar 2021: +100.4% vs market
Similar setups −0.6%All companies −3.3%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 1 beyond the range shown, drawn at the edge

Similar setups' median
−0.6%
All companies' median
−3.3%
Beat the market
50% vs 46%

50 past situations · 50 companies · 31 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
AARTIIND
Process Industries		 Jan 2021 38x15% +18%−13% +25%
KIMS
Health Services		 Sep 2024 70x17% +41%−3% +36%
METROBRAND
Retail Trade		 Apr 2025 71x20% 0%−23% −10%
SRF
Process Industries		 Mar 2021 31x14% +94%−10% +100%
METROPOLIS
Health Services		 Apr 2025 57x16% −6%−26% +5%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
RAMCOCEM
Non-Energy Minerals		 Jul 2020 27x12% −6%−20% +1%
TORNTPHARM
Health Technology		 Jan 2021 43x15% +35%−13% −25%
SYNGENE
Commercial Services		 Aug 2023 67x15% +29%−8% −24%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: P/E, 12-month momentum and ROCE. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to RAINBOW CHILDRENS MEDICARE LTD. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

ERIS LIFESCIENCESERIS
Health Technology
66%similar
debt/equityoperating margin
LEMON TREE HOTELSLEMONTREE
Consumer Services
63%similar
revenuemarket cap
GRANULES INDIAGRANULES
Health Technology
61%similar
ROCEEPS growth
PHOENIX MILLSPHOENIXLTD
Finance
61%similar
debt/equitypromoter holding
ASAHI INDIA GLASSASAHIINDIA
Consumer Durables
59%similar
debt/equitypromoter holding
METROPOLIS HEALTHCAREMETROPOLIS
Health Services
73%similar
market caprevenue
JUPITER LIFE LINE HOSP.JLHL
Health Services
68%similar
volatilityrevenue
GLOBAL HEALTHMEDANTA
Health Services
63%similar
ROCErevenue growth

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Aug '22

  1. OctValuationP/E fell below the 10th percentile of its own history to date (43.4x).
  2. SepPriceVolume reached 5.4x its 50-day median on 2026-09-25; price -2.7% that day.
  3. AprPriceVolume reached 26.0x its 50-day median on 2026-04-07; price +4.9% that day.
  4. MarPriceFell 34% from the Dec 2024 peak to the Mar 2026 low.
  5. MarPeer rankSlipped to the 3rd quartile of Health Services on EPS growth (from the 2nd quartile).
  6. JanValuationP/E fell below the 10th percentile of its own history to date (45.5x).
  7. JanPriceVolume reached 5.8x its 50-day median on 2026-01-22; price -2.5% that day.
  8. OctPriceVolume reached 9.5x its 50-day median on 2025-10-09; price +0.4% that day.
Show 22 earlier events
  1. SepPeer rankMoved into the 2nd quartile of Health Services on EPS growth (from the 3rd quartile).
  2. JulPriceVolume reached 6.9x its 50-day median on 2025-07-24; price +5.8% that day.
  3. AprPriceVolume reached 14.0x its 50-day median on 2025-04-04; price +2.6% that day.
  4. MarPriceVolume reached 5.8x its 50-day median on 2025-03-24; price +4.3% that day.
  5. NovPriceVolume reached 25.2x its 50-day median on 2024-11-04; price +5.2% that day.
  6. OctPriceRegained the 2024-05 peak, 3 months after the low.
  7. SepValuationP/E crossed above the 90th percentile of its own history to date (65.9x).
  8. SepPeer rankSlipped to the 3rd quartile of Health Services on EPS growth (from the 2nd quartile).
  9. SepPriceVolume reached 29.7x its 50-day median on 2024-09-26; price +1.9% that day.
  10. JulPriceFell 30% from the May 2024 peak to the Jul 2024 low.
  11. JunResultsRevenue (TTM) reached a new high of ₹1,297 cr.
  12. JunPeer rankSlipped to the 2nd quartile of Health Services on ROCE (from the top quartile).
  13. MayPriceVolume reached 17.8x its 50-day median on 2024-05-06; price +7.3% that day.
  14. FebPriceVolume reached 26.3x its 50-day median on 2024-02-28; price +11.1% that day.
  15. SepPriceVolume reached 7.1x its 50-day median on 2023-09-15; price +0.6% that day.
  16. JunResultsRevenue (TTM) reached a new high of ₹1,174 cr.
  17. JunPeer rankMoved into the top quartile of Health Services on ROCE (from the 2nd quartile).
  18. JunDebtDebt / equity fell below 1.0x (0.54x).
  19. MaySharesShare count is up 113.6% over 12 months.
  20. MayPriceVolume reached 6.6x its 50-day median on 2023-05-16; price +5.0% that day.
  21. DecPriceVolume reached 88.3x its 50-day median on 2022-12-05; price -1.7% that day.
  22. AugPriceVolume reached 25.6x its 50-day median on 2022-08-11; price +7.0% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history92 months · 2019-04 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1145.4x₹1820 cr17.3%17.0%0.5x
2026-1043.4x₹1820 cr17.6%17.0%0.5x
2026-0946.8x₹1820 cr17.6%17.0%0.5x
2026-0851.6x₹1703 cr17.1%17.0%0.5x
2026-0755.7x₹1703 cr17.1%17.0%0.5x
2026-0651.6x₹1703 cr17.1%17.0%0.5x
2026-0554.4x₹1613 cr17.8%19.0%0.5x
2026-0449.4x₹1613 cr17.8%19.0%0.5x
2026-0345.8x₹1613 cr17.8%19.0%0.5x
2026-0247.6x₹1566 cr17.4%19.0%0.5x
2026-0145.5x₹1566 cr17.4%19.0%0.5x
2025-1252.8x₹1566 cr17.4%19.0%0.5x
2025-1153.3x₹1538 cr17.6%19.0%0.5x
2025-1054.0x₹1538 cr17.6%19.0%0.5x
2025-0953.5x₹1538 cr17.6%19.0%0.5x
2025-0862.7x₹1515 cr16.7%19.0%0.5x
2025-0763.6x₹1515 cr16.7%19.0%0.5x
2025-0665.2x₹1515 cr16.7%19.0%0.5x
2025-0559.8x₹1486 cr19.0%19.0%0.6x
2025-0458.9x₹1486 cr19.0%19.0%0.6x
2025-0359.8x₹1486 cr19.0%19.0%0.6x
2025-0254.4x₹1424 cr18.5%19.0%0.6x
2025-0162.4x₹1424 cr18.5%19.0%0.6x
2024-1265.8x₹1424 cr18.5%19.0%0.6x
2024-1174.9x₹1340 cr17.2%19.0%0.6x
2024-1076.0x₹1340 cr17.2%19.0%0.6x
2024-0965.9x₹1340 cr17.2%19.0%0.6x
2024-0859.3x₹1297 cr17.3%19.0%0.6x
2024-0755.4x₹1297 cr17.3%19.0%0.6x
2024-0658.3x₹1297 cr17.3%19.0%0.6x
2024-0562.6x₹1174 cr20.0%24.0%0.5x
2024-0466.2x₹1174 cr20.0%24.0%0.5x
2024-0362.5x₹1174 cr20.0%24.0%0.5x
2024-0265.3x₹1174 cr20.0%24.0%0.5x
2024-0158.6x₹1174 cr20.0%24.0%0.5x
2023-1257.4x₹1174 cr20.0%24.0%0.5x
2023-1151.7x₹1174 cr20.0%24.0%0.5x
2023-1051.2x₹1174 cr20.0%24.0%0.5x
2023-0949.5x₹1174 cr20.0%24.0%0.5x
2023-0851.0x₹1174 cr20.0%24.0%0.5x
2023-0753.2x₹1174 cr20.0%24.0%0.5x
2023-0646.3x₹1174 cr20.0%24.0%0.5x
2023-0567.3x₹974 cr23.5%23.0%1.0x
2023-0453.8x₹974 cr23.5%23.0%1.0x
2023-0349.7x₹974 cr23.5%23.0%1.0x
2023-0250.4x₹974 cr23.5%23.0%1.0x
2023-0152.2x₹974 cr23.5%23.0%1.0x
2022-1250.3x₹974 cr23.5%23.0%1.0x
2022-1150.7x₹974 cr23.5%23.0%1.0x
2022-1046.9x₹974 cr23.5%23.0%1.0x
2022-0942.9x₹974 cr23.5%23.0%1.0x
2022-0841.5x₹974 cr23.5%23.0%1.0x
2022-0733.3x₹974 cr23.5%23.0%1.0x
2022-0631.7x₹974 cr23.5%23.0%1.0x
2022-05109.3x₹650 cr9.2%11.0%1.2x
2022-04—————
2022-03—————
2022-02—————
2022-01—————
2021-12—————
2021-11—————
2021-10—————
2021-09—————
2021-08—————
2021-07—————
2021-06—————
2021-05—————
2021-04—————
2021-03—————
2021-02—————
2021-01—————
2020-12—————
2020-11—————
2020-10—————
2020-09—————
2020-08—————
2020-07—————
2020-06—————
2020-05—————
2020-04—————
2020-03—————
2020-02—————
2020-01—————
2019-12—————
2019-11—————
2019-10—————
2019-09—————
2019-08—————
2019-07—————
2019-06—₹543 cr12.5%16.0%1.3x
2019-05—₹402 cr10.3%14.0%0.1x
2019-04—₹402 cr10.3%14.0%0.1x

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback